Summary:
Effects of Intensive Uric Acid Lowering Therapy with RDEA3170 (Verinurad) and Febuxostat in Patients with Chronic Kidney Disease
The purpose of this clinical research study is to evaluate signals of potential clinical benefit of the combination of RDEA3170 and Febuxostat in lowering concentrations of circulating uric acid and thus improving kidney or cardiovascular status of patients with hyperuricemia, albuminuria, and Type 2 diabetes (T2DM).
Qualified Participants Must:
• Inclusion Criteria:
- Serum Uric Acid >
•6.0 mg/dL - eGFR &ge
•30 mL/min/1.73 m2 - UACR between 30 mg/g and 3500 mg/g inclusive
- Diagnosed with T2DM
Exclusion Criteria:
- Treated with any drug for hyperuricemia in the 6 months preceding randomization.Drugs for hyperuricemia include all XO inhibitors (allopurinol, febuxostat and topiroxostat) and URAT1 inhibitors (lesinurad, RDEA3170, probenecid, and benzbromarone)
- Prior history of gout, unless prophylaxis therapy isn'
•t required - Patients who are pregnant, lactating, or planning to become pregnant
- Patients unsuitable or unable to undergo MRI assessment
•
Qualified Participants May Receive:
- Compensation for Time and Travel
- Study-Related Medication or Placebo
- Study-Related Exam by Licensed Professional